AI Stock Memo: CRSP - CRISPR Therapeutics - RankAlpha

CRSP

Rating buyAI Memo

CRISPR Therapeutics

As of 2026-01-23/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-01-23 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

—

Key catalyst

Partnerships / licensing announcements • 2026-04-23

Expected move: +29%

Biggest risk

Bear assumes trial failures, regulatory setbacks, or financing pressure that force dilution and compress valuation toward prior lows.

Invalidation

Break below $35 or thesis failure.

What would change my mind?

Bull assumes successful pivotal readouts, timely approvals, and early commercial traction that expand revenue and justify premium multiples.

Research note

Recommendation

buy

Confidence

medium

As of

2026-01-23

Base target

$69

p=60%

Bull target

$120

p=20%

Bear target

$35

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Near-term clinical data readouts
Regulatory approvals and early commercialization
Bull assumes successful pivotal readouts, timely approvals, and early commercial traction that expand revenue and justify premium multiples.

BearKey bullets

Competitive advances compressing addressable market
Need for dilutive financing
Pivotal trial failure or adverse safety signal

WatchKey bullets

Partnerships / licensing announcements

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $69 (p=60%)

Bull/Bear spread: +124% / -35%

Vs latest close: Bull +124% · Base +29% · Bear -35%

Scenario probabilities

Bull Target: $120 (p=20%)Base Target: $69 (p=60%)Bear Target: $35 (p=20%)

Commentary

Sentiment is mixed-to-constructive: consensus median (~$69) implies modest near-term upside, but a wide high/low spread signals event-driven volatility and divergent views across analysts [#SERP-1], [#SERP-3]. Near-term focus is on data and target revisions; long-term tone depends on commercialization evidence.

As of 2026-01-23 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bull assumes successful pivotal readouts, timely approvals, and early commercial traction that expand revenue and justify premium multiples.

Bear Case

Bear assumes trial failures, regulatory setbacks, or financing pressure that force dilution and compress valuation toward prior lows.

Drivers

Scannable catalysts and supporting factors

Near-term clinical data readouts
Regulatory approvals and early commercialization

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-01-23Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$69.00

Range (USD)

$32.00 - $120.00

Count

Query: CRISPR Therapeutics AG Common (CRSP) analyst consensus price target high low average

Crispr Therapeutics AG (CRSP) Stock Forecast, Price ... - TipRanks
Search result #1
The average price target is $69.00 with a high forecast of $105.00 and a low forecast of $40.00. The average price target represents a 28.95% change from the ...
Extracted: $69.00, $105.00, $40.00Open source
CRISPR Therapeutics AG: Target Price Consensus and Analysts ...
Search result #2
Consensus CRISPR Therapeutics AG ; Average target price. 83.46USD ; Spread / Average Target. +52.49% ; High Price Target. 315.00USD ; Spread / Highest target. + ...
Extracted: $83.46, $315.00Open source
CRSP Stock Forecast - CRISPR Therapeutics AG - Alpha Spread
Search result #3
According to Wall Street analysts, the average 1-year price target for CRSP is 72.34 USD with a low forecast of 32.32 USD and a high forecast of 115.5 USD. What ...
Extracted: $72.34, $32.32, $115.50Open source
CRISPR Therapeutics AG (CRSP) Price Targets
Search result #4
The forecasts range from a low of $32.00 to a high of $315.00. The average price target represents an increase of 51.05% from the last closing price of $54.73.
Extracted: $32.00, $315.00, $54.73Open source
CRISPR Therapeutics AG Stock Forecast | CRSP Price Target ...
Search result #5
The highest price target is $75.00, while the lowest is $50.00. Compared to the current price of $54.21, this represents a potential 14.4% upside .
Extracted: $75.00, $50.00, $54.21Open source
CRISPR Therapeutics (CRSP) Stock Price, News & Analysis
Search result #6
Price Target and Rating. Average Price Target for CRISPR Therapeutics: $68.35. High Price Target: $120.00. Low Price Target: $9.00. Potential Upside/Downside: + ...
Extracted: $68.35, $120.00, $9.00Open source

Scenarios

Bull Target (Scenario probability)

$120 / p=20% prob

Base Target (Scenario probability)

$69 / p=60% prob

Bear Target (Scenario probability)

$35 / p=20% prob

Price $54 as of 2026-05-27

Nearest Scenario: Base (∆ 29%)

Targets vs latest close: Bull +124% · Base +29% · Bear -35%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-04-23
Partnerships / licensing announcements
New collaborations or licenses could de-risk programs and add non-dilutive capital; timing is uncertain so a conservative window is used [#SERP-3].
Prob 20.00% • Move 15.00% • Priced-in 10.00%

Short-term Catalysts

Next few weeks

Near-term clinical data readouts
2026-04-23
Upcoming mid-to-late stage readouts could re-rate shares; positive efficacy/safety would lift valuation while negative results would drive sharp downside [#SERP-1].
Prob 40% • Move 25% • Priced-in 35%

Long-term Catalysts

Months to a year

Regulatory approvals and early commercialization
2027-01-23
Regulatory success and initial commercial uptake for lead indications would materially expand revenue and support multiple expansion; timing is multi-quarter [#SERP-2].
Prob 30% • Move 100% • Priced-in 20%

Risks

Competitive advances compressing addressable market
Need for dilutive financing
Pivotal trial failure or adverse safety signal
Regulatory delay or non-approval

Peers

Symbol	Summary
EDIT	Editas — CRISPR-focused developer with comparable clinical-stage risk and regulatory sensitivity.
NTLA	Intellia — platform peer across in vivo/ex vivo programs; useful for regulatory/readout comparisons.
BEAM	Beam — base-editing specialist; contrasts on modality and commercialization path but similar event-driven volatility.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: CRISPR Therapeutics AG Common (CRSP) analyst consensus price target high low average
Analysis date: 2026-01-23